IL2 and type 1 diabetes mellitus: This suggests that immunotherapy strategies currently aimed at supplementing IL-2 and boosting Treg function in T1D patients may potentially influence the microbiota in these patients and microbiota monitoring strategies could be investigated for determining response to therapy.